1. NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease;Kingwell;Nat Rev Drug Discov,2024
2. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: new insights and future directions;Alshehade;Life Sci,2022
3. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe;Lazarus;J Hepatol,2020
4. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments;Peng;Front Pharmacol,2020
5. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030;Estes;J Hepatol,2018